Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Torrent Pharmaceuticals demonstrated robust performance in Q1 FY26, driven by strong growth in branded markets, particularly India and Brazil.
- India business achieved 11% growth, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.
- Brazil witnessed substantial 16% constant currency growth, exceeding market growth of 5%.
- US generics business exhibited 19% growth, while Germany experienced 1% growth due to third-party supplier disruptions.
- Operating EBITDA margin reached 32.9% after adjusting for one-time acquisition expenses.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.